Glenmark Pharmaceuticals Ltd vs Indoco Remedies Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 09, 2026

Key Highlights

The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2207 as of 09 Jun 15:30 . The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 yearsThe P/E Ratio of Indoco Remedies Ltd changed from 28.6 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 yearsThe Market Cap of Indoco Remedies Ltd changed from ₹ 2658 crore on March 2021 to ₹ 2152 crore on March 2025 . This represents a CAGR of -4.14% over 5 years The revenue of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 3959 crore as compare to the Dec '25 revenue of ₹ 3945 crore. This represent the growth of 0.37% The revenue of Indoco Remedies Ltd for the Mar '26 is ₹ 479.31 crore as compare to the Dec '25 revenue of ₹ 446.34 crore. This represent the growth of 7.39% The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '26 is ₹ 578.28 crore as compare to the Dec '25 ebitda of ₹ 729.88 crore. This represent the decline of -20.77% The ebitda of Indoco Remedies Ltd for the Mar '26 is ₹ 53.41 crore as compare to the Dec '25 ebitda of ₹ 26.34 crore. This represent the growth of 102.77% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 301.32 crore over 8 quarters. This represents a CAGR of -5.89% The net profit of Indoco Remedies Ltd changed from ₹ 1.82 crore to ₹ -23.68 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 yearsThe Dividend Payout of Indoco Remedies Ltd changed from 14.96 % on March 2021 to -21.11 % on March 2025 . This represents a CAGR of NaN% over 5 years .

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

About Indoco Remedies Ltd

Indoco Remedies Limited, incorporated on August 23, 1947 is a Mumbai-based pharmaceutical company focused on formulations, with some presence in contract manufacturing and research.
The Company headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries.
The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). Indoco, a USD 212 million company has 11 manufacturing facilities, 7 of which are for FDFs and 4 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. Currently, Indoco has a presence in therapeutic segments including anti-infective, anti-cold preparation, opthalmic, antispasmodic, stomatology, anti-inflammatory and anti-fungal.

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Indoco Remedies Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Indoco Remedies Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 62,288 Cr while Market cap of Indoco Remedies Ltd is 1,897 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Indoco Remedies Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Indoco Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Indoco Remedies Ltd?

As of June 9, 2026, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2207.25. On the other hand, Indoco Remedies Ltd stock price is INR ₹205.55.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Indoco Remedies Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Indoco Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.